Cargando…
Is a BTKi or BCL2i preferable for first “novel” therapy in CLL? The case for BTKis
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
American Society of Hematology
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8864648/ https://www.ncbi.nlm.nih.gov/pubmed/34965291 http://dx.doi.org/10.1182/bloodadvances.2019001204 |
| _version_ | 1784655500679315456 |
|---|---|
| author | Brem, Elizabeth A. O’Brien, Susan |
| author_facet | Brem, Elizabeth A. O’Brien, Susan |
| author_sort | Brem, Elizabeth A. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8864648 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | American Society of Hematology |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-88646482022-02-23 Is a BTKi or BCL2i preferable for first “novel” therapy in CLL? The case for BTKis Brem, Elizabeth A. O’Brien, Susan Blood Adv Point American Society of Hematology 2022-02-22 /pmc/articles/PMC8864648/ /pubmed/34965291 http://dx.doi.org/10.1182/bloodadvances.2019001204 Text en © 2022 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved. |
| spellingShingle | Point Brem, Elizabeth A. O’Brien, Susan Is a BTKi or BCL2i preferable for first “novel” therapy in CLL? The case for BTKis |
| title | Is a BTKi or BCL2i preferable for first “novel” therapy in CLL? The case for BTKis |
| title_full | Is a BTKi or BCL2i preferable for first “novel” therapy in CLL? The case for BTKis |
| title_fullStr | Is a BTKi or BCL2i preferable for first “novel” therapy in CLL? The case for BTKis |
| title_full_unstemmed | Is a BTKi or BCL2i preferable for first “novel” therapy in CLL? The case for BTKis |
| title_short | Is a BTKi or BCL2i preferable for first “novel” therapy in CLL? The case for BTKis |
| title_sort | is a btki or bcl2i preferable for first “novel” therapy in cll? the case for btkis |
| topic | Point |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8864648/ https://www.ncbi.nlm.nih.gov/pubmed/34965291 http://dx.doi.org/10.1182/bloodadvances.2019001204 |
| work_keys_str_mv | AT bremelizabetha isabtkiorbcl2ipreferableforfirstnoveltherapyincllthecaseforbtkis AT obriensusan isabtkiorbcl2ipreferableforfirstnoveltherapyincllthecaseforbtkis |